Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
WALTHAM, Mass., Nov. 08, 2017 -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2017 London Healthcare Conference on November 15, 2017 at 2:00 p.m. GMT (9:00 a.m. EST).
The presentation will be web cast and accessible through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com.
About Minerva Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, in clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
